Synaffix Expands its Existing Collaboration with ADC Therapeutics to Explore Two Additional Programs

Shots:

  • Synaffix to receive upfront, milestone and royalty payments tied to each program while ADC gets a non-exclusive right for two additional programs, bringing the total number of programs to five
  • ADC also get access to Synaffix’ GlycoConnect platform, including DAR1 technology enabling stable attachment of just a single drug per antibody
  • In 2016, the two companies collaborated, under which ADC Therapeutics is responsible for the research, development, manufacturing, and commercialization of any resulting ADC products while Synaffix is responsible for the manufacturing of components specifically related to its ADC technologies

Click here to read full press release/ article | Ref: Businesswire | Image: Synaffix